Prophylactic and therapeutic anti-TRAMP-C1 prostate cancer immunity elicited by <i>in vivo</i> immunization with DCLV-PSCA.

<p>(A, B) Male C57BL/6 mice were immunized with 8×10⁷ TU of DCLV-PSCA, mock vector DC-LV-Null, or PBS control at the base of tail. Ten days post-immunization, these mice were challenged subcutaneously with 5×10⁵ of TRAMP-C1 tumor cells. Tumor growth curves were monitored with a fine caliper, and tumor volume was calculated based on the largest perpendicular diameters (mm³), according to the formula <i>V = ab²π/6</i>, where <i>a</i> and <i>b</i> are the largest perpendicular diameters. Representative Kaplan Meyer survival curve for prophylactic tumor challenge (n = 12). (C, D) Male C57BL/6 mice were implanted with 5×10⁵ TRAMP-C1 tumor cells subcutaneously, and 18 days later, these tumor-bearing mice were treated with 8×10⁷ TU of DCLV-PSCA (n = 12) or DCLV-Null (n = 12) at the base of tail. Tumor volume was monitored and calculated as previously described. Representative Kaplan Meyer survival curve for therapeutic tumor challenge. (***: <i>P</i><0.001; Log-rank (Mantel-Cox) test. Error bars represent SEM.) All experiments were repeated twice and the representative data is shown.